Emerging pathways and promising agents with possible disease modifying effect in osteoarthritis treatment

Zdravko Jotanovic, Radovan Mihelic, Branko Sestan

  • 1Clinic for Orthopaedic Surgery Lovran, School of Medicine, University of Rijeka, Marsala Tita 1, PO Box 51415 Lovran, Croatia. zjotanov@inet.hr.

Current Drug Targets
|March 7, 2014
PubMed

Insights

Current osteoarthritis treatments only manage symptoms, not disease progression. New disease-modifying OA drugs (DMOADs) are urgently needed, potentially through combination therapies, to effectively treat this complex condition.

Area of Science:

  • Orthopedics and Rheumatology
  • Pharmacology
  • Regenerative Medicine

Background:

  • Current osteoarthritis (OA) treatments offer limited efficacy, primarily alleviating symptoms without halting disease progression or structural damage.
  • There is a significant unmet clinical need for safe and effective disease-modifying osteoarthritis drugs (DMOADs).

Purpose of the Study:

  • To review emerging therapeutic strategies and agents targeting OA.
  • To discuss novel pathways and potential DMOADs for OA treatment and understanding OA pathophysiology.

Main Methods:

  • Review of current and emerging OA treatment modalities.
  • Discussion of novel agents targeting cartilage, synovial membrane, and subchondral bone.
  • Exploration of stem cell and gene therapy approaches for OA.

Main Results:

  • Existing OA therapies are insufficient for disease modification.
  • Emerging strategies show promise for developing DMOADs.
  • OA is a heterogeneous disease, suggesting combination therapy may be optimal.

Conclusions:

  • There is an urgent need for DMOADs to alter OA progression.
  • Future OA treatment may involve combination therapies rather than single agents.
  • Further research is required to identify effective DMOAD combinations for OA.